MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia

R.R. Umarov, N.G. Sokhibnazarov (Tashkent, Uzbekistan)

Meeting: 2016 International Congress

Abstract Number: 1380

Keywords: Cognitive dysfunction, Dementia

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Cognition

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To study the value of various neuropsychological scales to determine the degree of cognitive dysfunction in patients with posttraumatic subcortical Parkinsonian dementia, during the neuroprotective, antiParkinsonian therapy.

Background: Dementia is a degenerative disorder involving the compromise of multiple domains of cognition. This definition excludes acute confusion of any cause and also chronic focal brain syndromes, in particular the amnesic syndrome.

Methods: The study included 11 patients (6 male and 5 female) who are hospitalized in the neurology department of TMA from the (2013-2014)year, aged 42 to 73 years (middle age 50,2 ± 7,4 years) suffering with posttraumatic subcortical Parkinsonian dementia. To assessment neurological status used brief scale to assessment cognitive status Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA). Patients were divided into 2 groups: the main group consisted of 6 patients with traditional therapy was appointed «Memantin» during the 2 months. The control group consisted of 5 patients who received only conventional therapy without «Memantin».

Results: In the study group patients, who take «Memantin» cognitive function are improved (memory, thinking, comprehension) to 32 % than in the control group. It was found that prior to treatment, patients in the study group took 19.2 on the MMSE, and 20.1 point from the MoCA. Patients in the control group, respectively, 19.6 and 20.4. After treatment, the patients of the main group on the MMSE score increased to 26.4 points, patients in the control group score been 24.1 points. By the MoCA the study group scored 25.2 points, patients in the control group 21.6 points.

Conclusions: 1. The use of scales to determine the cognitive dysfunctions enables to improved identification degree of cognitive dysfunctions. 2. The use of a neuroprotective, antiParkinsonian drug «Memantin» in patients with posttraumatic subcortical Parkinsonian dementia to improved the condition of patients and reduce the severity of the degree of cognitive impairment, frequent in this pathology.

To cite this abstract in AMA style:

R.R. Umarov, N.G. Sokhibnazarov. Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/treatment-and-diagnosis-with-the-use-of-neuropsychological-scale-in-patients-with-posttraumatic-subcortical-parkinsonian-dementia/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/treatment-and-diagnosis-with-the-use-of-neuropsychological-scale-in-patients-with-posttraumatic-subcortical-parkinsonian-dementia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley